Compare SFL & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFL | HROW |
|---|---|---|
| Founded | 2003 | 1998 |
| Country | Bermuda | United States |
| Employees | N/A | 373 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2004 | N/A |
| Metric | SFL | HROW |
|---|---|---|
| Price | $10.45 | $41.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $12.00 | ★ $69.86 |
| AVG Volume (30 Days) | ★ 1.4M | 775.2K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | ★ 7.05% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $31.62 |
| Revenue Next Year | $13.07 | $50.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.73 | $28.54 |
| 52 Week High | $12.94 | $54.98 |
| Indicator | SFL | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 35.21 | 62.90 |
| Support Level | $9.83 | $40.61 |
| Resistance Level | $11.24 | $41.94 |
| Average True Range (ATR) | 0.33 | 2.13 |
| MACD | -0.05 | 0.56 |
| Stochastic Oscillator | 15.11 | 72.82 |
SFL Corp Ltd is an international ship-owning and chartering company. The company is engaged in transporting crude oil and oil products, dry bulk and containerized cargoes, freight of rolling cargo, and offshore drilling and related activities. The company operates as a single reportable segment, generating revenue from long-term, fixed-rate charters. Its Additional revenue sources include sales-type lease interest income, voyage charter and pool revenues, and drilling contract revenues.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.